on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Stake in Avadel Pharmaceuticals
The Vanguard Group, Inc. has submitted a disclosure under Form 8.3 of the Irish Takeover Panel Act regarding its stake in Avadel Pharmaceuticals plc. As of November 14, 2025, Vanguard controls 5,527,141 ordinary shares, which equates to 5.67% of Avadel's relevant securities.
The disclosure does not involve any parties other than Avadel Pharmaceuticals, and there were no dealings in cash-settled or stock-settled derivative transactions. A small purchase of 1,927 ordinary shares was made at a price of 23.56 USD per unit.
No agreements, indemnities, or options related to these securities have been disclosed. The filing confirms a straightforward shareholder position without additional financial instruments or arrangements affecting Avadel's shares.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news